MedTech Outlook Magazine: Specials Magazine

What gap exists between simple gravity systems and complex electronic infusion pumps? Infusion delivery today operates between two extremes. As David Duncan, MD, founder, frames it, “I call one A and the other Z, and there’s a massive gap in between.” It is precisely this gap that MonuMedical is addressing. It is creating a more intuitive pathway for care delivery that aligns closely with the realities clinicians face every day. Gravity-based systems offer accessibility and ease of use, but depend heavily on manual estimation and continuous oversight. Electronic infusion pumps offer greater precision but introduce complexity through programming, calculations and training requirements. “On one side, you have simple but inaccurate and unreliable methods. On the other hand, you have highly complex systems that require significant training, time and setup,” says Duncan. How does simplifying infusion calculations reduce cognitive load and improve clinical workflow efficiency? This gap reflects an operational reality that clinicians have adapted to over time. Tasks such as calculating infusion rates, preparing medications across multiple steps and managing equipment that is not designed for mobility are often accepted as part of routine care. In high-pressure scenarios, these steps result in time delays, increased cognitive load and higher risk of dosing errors.

What factors influence the consistency of outcomes in microneedling treatments across clinics? In microneedling, stronger results depend on more than the device alone. They are shaped by how the skin is prepared, how the procedure is performed and how recovery is supported afterward. Across concerns such as acne, uneven texture, pigmentation and age-related skin changes, outcomes are often stronger when those stages are managed as one connected pathway. In many clinics, devices, products and protocols still operate separately, making consistent outcomes harder to achieve. Dp Derm addresses that gap by structuring microneedling as a protocol-led treatment model designed to improve consistency from preparation through recovery and help clinics deliver more confident, results-driven care. At the center is Dermapen 4, supported by the Dp Dermaceuticals range for preparation, in-procedure use and post-treatment care. Practitioner education, indication-specific protocols, provider resources and home care products help clinics manage treatment more consistently while giving clients a more complete experience from start to finish. “It’s about providing a bespoke approach to microneedling. A Dermapen treatment is designed as an elevated treatment, not just a standard microneedling procedure,” says Joel Marshall, CEO..

What challenges do caregivers face when managing mobility for dependent individuals daily? Across the country, millions of Family Caregivers shoulder a responsibility that is as physically demanding as it is emotionally consuming. Everyday tasks like getting a loved one out of the house, often involve lifting, pushing, and maneuvering heavy mobility equipment, at the expense of the Caregiver’s own health. How widespread is caregiver responsibility, and what limitations exist in current mobility devices? What makes this reality even more challenging is its scale. Family Caregivers account for nearly 85 percent of all care, many supporting individuals living with Alzheimer’s, dementia, or Parkinson’s. In many cases, patients cannot safely operate a joystick or control powered mobility devices, and the responsibility falls entirely on the Caregiver. Yet most devices were never designed with Caregivers in mind. Why has CareGlider developed a new approach centered on caregiver usability and safety? It is within this gap that CareGlider has emerged, offering a fundamentally different approach to mobility that puts Caregivers at the center of the design. Rather than expecting them to adapt to bulky, traditional equipment, the system is built specifically to reduce strain while maintaining control and safety. At its core is a Caregiver-controlled mobility device that enables smooth, assisted transport for individuals who cannot operate powered chairs themselves, while significantly reducing Caregiver’s burden. “We advocate for Caregivers while developing products created specifically to support them,” says David Carson, CEO. “Caregivers are the unsung heroes of our healthcare system, and they deserve tools that protect their health, preserve their independence, and make daily life more manageable.”.

What gaps exist in current light therapy solutions for consistent clinical outcomes? Bedrock Bioscience was developed out of direct clinical experience, where treating patients consistently highlighted the need for reliable, outcome-driven medical devices. In working with complex conditions over thousands of cases, it became clear that many available light therapy solutions lacked the consistency, innovation, and clinical grounding required to deliver predictable results for at-home patient treatments. To address this gap, Bedrock Bioscience designs LED light therapy systems specifically for medical practitioners. These devices are built to meet strict FDA standards and clearance requirements, ensuring that doctors can deliver treatments with confidence and consistency. “There’s a whole other level of performance and quality with our devices that you don’t find with over-the-counter products. Since the people we sell to are doctors, we want to make sure they are getting the best quality product,” says Dr. Phil Straw, Co-founder. From the first treatment to ongoing patient care, Bedrock Bioscience emphasizes clinical efficacy, reproducibility, and practitioner trust as central to its approach..

Medical device innovators often face a recurring challenge. Regulatory requirements and quality systems are treated as late-stage obligations rather than integrated components of development. This disconnect leads to rework, delayed submissions and uncertainty during regulatory review, particularly when critical data is incomplete or poorly structured. Webster MedTech Consulting addresses this challenge by embedding regulatory strategy into early development decisions. Its approach focuses on aligning engineering, quality and regulatory pathways from the start so that every data point generated contributes directly to submission readiness. “When regulatory strategy is embedded from the earliest engineering decisions, data generated throughout development becomes a direct input to faster, more defensible submissions,” says Caroline Webster, founder and principal consultant. Aligning Data and Strategy From the Start A central issue for many teams is the disconnect between data generation and decision-making. Engineering and testing data are often collected without a clear structure, limiting their value in regulatory planning and increasing the likelihood of last-minute remediation. Webster MedTech Consulting addresses this through alignment-first development. Each engagement begins with a structured analysis of existing technical data, including laboratory, benchtop and clinical outputs. This process identifies gaps not only in documentation but also in the underlying evidence required to support regulatory claims. .